Short answer
Enliven Therapeutics, Inc. (ELVN) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Enliven Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026
- Detailed results and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 Phase 1 data support ELVN-001 advancement, with 61% overall MMR and 48% MMR by 24 weeks at 80 mg QD
- Earlier-line patients showed 67% overall MMR and 55% MMR by 24 weeks, strengthening the targeted Phase 3 opportunity
- FDA aligned on key ENABLE-2 design elements, including 80 mg QD and physician’s-choice TKI comparator
- $895.2 million liquidity, up from $462.6 million at December 31, 2025, supports expected cash runway into 2030
- Net loss widened to $32.5 million from $25.3 million as R&D increased to $29.0 million from $21.5 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Enliven Therapeutics, Inc. 8-K filings
Get the next ELVN 8-K as it lands
Follow ELVN for push alerts, or ask the research agent what this filing means.